MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients

被引：60

作者：

Chiusolo, Patrizia ^{[1
]}

Reddiconto, Giovanni ^{[1
]}

Farina, Giuliana ^{[1
]}

Mannocci, Alice ^{[2
]}

Fiorini, Alessia

Palladino, Mariangela ^{[1
]}

La Torre, Giuseppe ^{[2
]}

Fianchi, Luana ^{[1
]}

Sora, Federica ^{[1
]}

Laurenti, Luca ^{[1
]}

Leone, Giuseppe ^{[1
]}

Sica, Simona ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Hematol, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Inst Hyg, Epidemiol & Biostat Unit, Rome, Italy

来源：

LEUKEMIA RESEARCH | 2007年 / 31卷 / 12期

关键词：

ALL; MTHFR; outcome; polymorphisms; toxicity;

D O I：

10.1016/j.leukres.2007.03.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently the influence of polymorphisms of different genes involved in metabolism of chemoterapic agents have been studied especially in childhood acute lymphoblastic leukemia (ALL). We evaluated the influence of C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms on time to relapse and survival and on methotrexate (MTX) toxicity in 82 ALL adult patients. Relapse free survival and event free survival between homozygous wild-type and variant patients in both polymorphisms were not significantly different. However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p = 0.02). In the same subgroup we confirmed the role of 677TT variant on toxicity during MTX treatment (p = 0.003). (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1669 / 1674

页数：6

共 25 条

[1] Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study [J].

Annino, L ;

Vegna, ML ;

Camera, A ;

Specchia, G ;

Visani, G ;

Fioritoni, G ;

Ferrara, F ;

Peta, A ;

Ciolli, S ;

Deplano, W ;

Fabbiano, F ;

Sica, S ;

Di Raimondo, F ;

Cascavilla, N ;

Tabilio, A ;

Leoni, P ;

Invernizzi, R ;

Baccarani, M ;

Rotoli, B ;

Amadori, S ;

Mandelli, F .

BLOOD, 2002, 99 (03) :863-871

[2] Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia [J].

Aplenc, R ;

Thompson, J ;

Han, P ;

La, M ;

Zhao, HQ ;

Lange, B ;

Rebbeck, T .

CANCER RESEARCH, 2005, 65 (06) :2482-2487

[3] Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement [J].

Bailey, LB ;

Gregory, JF .

JOURNAL OF NUTRITION, 1999, 129 (05) :919-922

[4] Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy [J].

Cheok, MH ;

Evans, WE .

NATURE REVIEWS CANCER, 2006, 6 (02) :117-129

[5]

Chiusolo P, 2004, HAEMATOLOGICA, V89, P139

[6] Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate [J].

Chiusolo, P ;

Reddiconto, G ;

Casorelli, I ;

Laurenti, L ;

Sorà, F ;

Mele, L ;

Annino, L ;

Leone, G ;

Sica, S .

ANNALS OF ONCOLOGY, 2002, 13 (12) :1915-1918

[7]

De Stefano V, 1998, THROMB HAEMOSTASIS, V79, P686

[8] The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia [J].

Franco, RF ;

Simöes, BP ;

Tone, LG ;

Gabellini, SM ;

Zago, MA ;

Falcao, RP .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :616-618

[9] A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].

FROSST, P ;

BLOM, HJ ;

MILOS, R ;

GOYETTE, P ;

SHEPPARD, CA ;

MATTHEWS, RG ;

BOERS, GJH ;

DENHEIJER, M ;

KLUIJTMANS, LAJ ;

VANDENHEUVEL, LP ;

ROZEN, R .

NATURE GENETICS, 1995, 10 (01) :111-113

[10] Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia [J].

Krajinovic, M ;

Lemieux-Blanchard, É ;

Chiasson, S ;

Primeau, M ;

Costea, I ;

Moghrabi, A .

PHARMACOGENOMICS JOURNAL, 2004, 4 (01) :66-72

← 1 2 3 →